D-MANNOSE LTD

Financial Health Score: D- (Critical but Stabilising)

While the business is currently in a state of technical insolvency, exhibiting symptoms of severe financial anaemia, the latest results show a remarkable and encouraging recovery in trading profitability. The patient is still in the emergency room, but vital signs are finally moving in the right direction.

1. Key Vital Signs

• Shareholders' Funds (Net Assets): -£45,995 Interpretation: This is a symptom of chronic financial anaemia. The business has negative equity, meaning its liabilities exceed its assets. However, this is a significant improvement from the prior year (£-100,745), indicating a strong "transfusion" from trading profits.
• Current Ratio (Liquidity): 0.57 Interpretation: A healthy current ratio is typically above 1.0. At 0.57, the business has shortness of breath—only 57p of current assets to cover every £1 of short-term debt. This indicates a high risk of a cash flow cardiac arrest if creditors demand payment.
• Cash at Bank: £2,146 Interpretation: Dangerously low blood pressure. With only £2k in the bank, the business has virtually no financial immune system to handle unexpected shocks or dips in trade.
• Secured Bank Debt: £100,713 Interpretation: High cholesterol clogging the arteries. Secured debt has nearly doubled from £57,862 in 2024. While this cash injection may have funded recent trading, it significantly increases the risk of severe complications if trading conditions change.
• Estimated Profitability: ~£54,750 Interpretation: The pulse is strengthening. By comparing the movement in the Profit & Loss reserve from -£102,745 to -£47,995, we can see the business generated a substantial profit this year, a massive turnaround from previous years of decline.

2. Diagnosis

The patient is suffering from Chronic Insolvency with Acute Liquidity Strain, but is currently experiencing a Strong Trading Recovery.

Looking at the medical history, D-Mannose Ltd was remarkably healthy in 2017 (Net Assets of £72k). However, an undiagnosed illness caused the business to haemorrhage cash between 2018 and 2022, plunging it into deep negative equity (£-126k).

The latest accounts reveal that the business has undergone a radical treatment plan. Despite carrying heavy debts, the company generated an estimated £54,750 in profit during the 2025 financial year. This is a testament to a revitalised trading model. However, the balance sheet structure remains highly precarious. The business is heavily reliant on stock (£52,424) and debtors (£30,913) to meet its obligations, while carrying a massive £149,020 in current liabilities. The near-doubling of the bank overdraft/loan to over £100k suggests the business is relying heavily on external financing to fund its working capital. The patient is surviving, but on life support from the bank.

3. Recommendations

To restore the business to full financial health, the following interventions are prescribed:

1. Cash Flow Resuscitation: The £2,146 cash balance is dangerously low. Focus on accelerating the collection of debtors (£30,913) and consider rationalising stock levels (£52,424) to convert assets into much-needed cash. Do not allow stock to sit idle on the shelves.
2. Debt Management Plan: With nearly £150k due within one year, the business must carefully manage creditor payments. Negotiate extended payment terms with suppliers where possible to ease the immediate pressure on cash flow.
3. Review Secured Borrowing: The jump in bank debt to £100k must be monitored. Ensure the terms of this debt are sustainable and that the interest payments are not swallowing the hard-earned trading profits.
4. Continue the Profitability Treatment: The estimated £54k profit is the best medicine this business has had in years. Scrutinise what drove this success—whether it was margin improvement, cost-cutting, or volume growth—and embed these practices into the business's DNA to continue the climb back to positive net assets.